EP2160408A1 - USE OF ANTIBODIES AGAINST THE CD52 ANTIGEN FOR THE TREATMENT OF NEUROLOGICAL DISORDERS, PARTICULARLY TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY AND ALZHEIMER'S DISEASE